In his State of the Union address on Tuesday evening, US President Donald Trump including some positive comments on the need for new medicines, and the work of the Food and Drug Administration, but also re-committed to lowering drug prices, though not everyone finds this convincing.
He stated: “One of my greatest priorities is to reduce the price of prescription drugs. In many other countries, these drugs cost far less than what we pay in the United States. And it’s very, very unfair. That is why I have directed my administration to make fixing the injustice of high drug prices one of my top priorities for the year. And prices will come down substantially. Watch.”
That might sound like a declaration of war on pharma. It’s not. Unless and until Trump comes out with real proposals with a shot of passing Congress that can reduce drug prices, it’s just more kayfabe, a fake attack on an industry that he has declined to confront in any real way, according to an analysis of the speech by Vox Media.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze